BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24036854)

  • 1. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.
    Shah V; Taratula O; Garbuzenko OB; Taratula OR; Rodriguez-Rodriguez L; Minko T
    Clin Cancer Res; 2013 Nov; 19(22):6193-204. PubMed ID: 24036854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.
    Taratula O; Kuzmov A; Shah M; Garbuzenko OB; Minko T
    J Control Release; 2013 Nov; 171(3):349-57. PubMed ID: 23648833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
    Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
    Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
    Taratula O; Garbuzenko OB; Chen AM; Minko T
    J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery.
    Taratula O; Garbuzenko OB; Kirkpatrick P; Pandya I; Savla R; Pozharov VP; He H; Minko T
    J Control Release; 2009 Dec; 140(3):284-93. PubMed ID: 19567257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer.
    Kala S; Mak AS; Liu X; Posocco P; Pricl S; Peng L; Wong AS
    J Med Chem; 2014 Mar; 57(6):2634-42. PubMed ID: 24592939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
    Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.
    Chen J; Wang J; Chen D; Yang J; Yang C; Zhang Y; Zhang H; Dou J
    BMC Cell Biol; 2013 Jan; 14():7. PubMed ID: 23368632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
    Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel targeted co-delivery nanosystem for enhanced ovarian cancer treatment via multidrug resistance reversion and mTOR-mediated signaling pathway.
    Wang X; Xiong T; Cui M; Li N; Li Q; Zhu L; Duan S; Wang Y; Guo Y
    J Nanobiotechnology; 2021 Dec; 19(1):444. PubMed ID: 34949180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
    Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
    Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo.
    Li CZ; Liu B; Wen ZQ; Li HY
    Folia Biol (Praha); 2008; 54(6):180-6. PubMed ID: 19393131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.